# GSK positive results for phase III RSV vaccine candidate

- Link: https://www.directorstalkinterviews.com/gsk-positive-results-for-phase-iii-rsv-vaccine-candidate/4121068039
- Published: 2022-06-10T07:31:06+01:00
- Author: Amilia Stone

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**(
[LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l))
has announced positive headline results from a pre-specified efficacy interim analysis
of the AReSVi 006 phase III trial. The interim analysis was reviewed by an Independent
Data Monitoring Committee, and the primary endpoint was exceeded with no unexpected
safety concerns observed. AReSVi 006 is a phase III trial investigating GSK’s respiratory
syncytial virus (RSV) vaccine candidate for adults aged 60 years and above.

> **Dr Hal Barron, Chief Scientific Officer and President, R&D, GSK**, said: “These
> data suggest our RSV vaccine candidate offers exceptional protection for older
> adults from the serious consequences of RSV infection. RSV remains one of the 
> few major infectious diseases without a vaccine, and these data have the potential
> to meaningfully impact the treatment of RSV and may reduce the 360,000 hospitalisations
> and more than 24,000 deaths worldwide each year. Given the importance of these
> data, we plan to engage with regulators immediately and anticipate regulatory 
> submissions in the second half of 2022.”

Results from this phase III trial will be presented in a peer-reviewed publication
and at an upcoming scientific meeting. The AReSVi 006 trial will continue to evaluate
both an annual revaccination schedule and longer-term protection over multiple seasons
following one dose of the RSV older adult (OA) vaccine candidate.

GSK’s RSV OA vaccine candidate contains a recombinant subunit prefusion RSV F glycoprotein
antigen (RSVPreF3) combined with GSK’s proprietary AS01 adjuvant. AS01 is used with
several of GSK’s established adjuvanted vaccines. The antigen plus adjuvant combination
may help overcome the natural age-related decline in immunity that contributes to
the challenge of protecting older adults from RSV disease.

Share on:
